Scientific Sessions 2024
/
Biomarkers in ACS
/
Reverse J-shaped Associations of Serum Hypoxia-inducible Factor 1α Levels With All-cause Mortality in Patients With Suspected or Known Coronary Artery Disease: The ANOX Study
American Heart Association
11
0
Final ID: MDP582
Reverse J-shaped Associations of Serum Hypoxia-inducible Factor 1α Levels With All-cause Mortality in Patients With Suspected or Known Coronary Artery Disease: The ANOX Study
Abstract Body (Do not enter title and authors here): Background: Hypoxia-inducible factor-1 (HIF-1) is a heterodimeric transcription factor composed of a constitutively expressed β subunit (HIF-1β) and an oxygen-dependent α subunit (HIF-1α). HIF-1α has an important protective effect on the pathophysiology underlying coronary artery disease (CAD). However, the association between serum HIF-1α levels and mortality in patients with suspected or known CAD is unknown. Methods and Results: Serum levels of HIF-1α were measured in 2,418 patients with suspected or known CAD using a commercially available enzyme-linked immunosorbent assay kit (sensitivity, 30 pg/mL). The outcomes were all-cause death, cardiovascular (CV) death, and non-CV death. Patients were divided into 5 groups according to HIF-1α levels; below the sensitivity (Q0, <30 pg/mL) and quartiles of measurable HIF-1α levels (Q1, 31-127; Q2, 128-303; Q3, 307-765; Q4, 774-4131 pg/mL). Patients were followed up over a 6-year period. During the follow-up, 536 (22.2%) deaths occurred, including 166 (6.9%) CV deaths, 326 (13.5%) non-CV deaths, and 44 (1.8%) undetermined deaths. At baseline, HIF-1α levels were significantly and inversely associated with the rate of current smoker (P<0.001), and showed significant U-shaped associations with age (P=0.016) and high-sensitivity C-reactive protein levels (P<0.001). Interestingly, HIF-1α levels exhibited U-shaped associations with incidence of all-cause, CV death, and non-CV death (Figure 1). Since the rates of incident outcomes were similar among Q1-Q3, we combined these 3 groups into the reference group for Cox proportional hazard analyses thereafter. After adjustment for potential clinical confounders and established CV biomarkers, the low HIF-1α level (Q0) was significantly associated with all-cause death (adjusted hazard ratio [aHR], 1.38; 95% confidence interval [CI], 1.02–1.91), but not with CV death (aHR, 1.12; 95% CI, 0.68–1.97) or non-CV death (aHR, 1.45; 95% CI, 0.98–2.23), while the high HIF-1α level (Q4) was not significantly associated with all-cause death (aHR, 1.12; 95% CI, 0.66–1.86), CV death (aHR, 0.76; 95% CI, 0.28–1.86), or non-CV death (aHR, 1.17; 95% CI, 0.58–2.25). Conclusions: We first demonstrated that serum HIF-1α levels exhibited a reverse J-shaped association with the risk of all-cause mortality in patients with suspected or known CAD.
Iguchi, Moritake
( NHO Kyoto Medical Center
, Kyoto
, Japan
)
Takenaka, Takashi
( NHO Hokkaido Medical Center
, Sapporo
, Japan
)
Morita, Yukiko
( NHO Sagamihara National Hospital
, Sagamihara
, Japan
)
Nakamura, Toshihiro
( NHO Kyushu Medical Center
, Fukuoka
, Japan
)
Fujimoto, Kazuteru
( NHO Kumamoto Medical Center
, Kumamoto
, Japan
)
Matsubara, Hiromi
( NHO Okayama Medical Center
, Okayama
, Japan
)
Kato, Toru
( NHO Tochigi Medical Center
, Utsunomiya
, Japan
)
Nakayama, Takumi
( NHO Kyoto Medical Center
, Kyoto
, Japan
)
Maeda, Yuka
( NHO Kyoto Medical Center
, Kyoto
, Japan
)
Masunaga, Nobutoyo
( NHO Kyoto Medical Center
, Kyoto
, Japan
)
Ishii, Mitsuru
( NHO Kyoto Medical Center
, Kyoto
, Japan
)
Kotani, Kazuhiko
( Jichi Medical University
, Shimotsuke
, Japan
)
Abe, Mitsuru
( NHO Kyoto Medical Center
, Kyoto
, Japan
)
Akao, Masaharu
( NHO Kyoto Medical Center
, Kyoto
, Japan
)
Hasegawa, Koji
( NHO Kyoto Medical Center
, Kyoto
, Japan
)
Wada, Hiromichi
( NHO Kyoto Medical Center
, Kyoto
, Japan
)
Matsuda, Morihiro
( NHO Kure Medical Center and Chugoku Cancer Center
, Kure
, Japan
)
Ajiro, Yoichi
( NHO Yokohama Medical Center
, Yokohama
, Japan
)
Shinozaki, Tsuyoshi
( NHO Sendai Medical Center
, Sendai
, Japan
)
Sakagami, Satoru
( NHO Kanazawa Medical Center
, Kanazawa
, Japan
)
Yonezawa, Kazuya
( NHO Hakodate National Hospital
, Hakodate
, Japan
)
Shimizu, Masatoshi
( NHO Kobe Medical Center
, Kobe
, Japan
)
Funada, Junichi
( NHO Ehime Medical Center
, Toon
, Japan
)
Author Disclosures:
Moritake Iguchi:DO NOT have relevant financial relationships
| Takashi Takenaka:DO NOT have relevant financial relationships
| Yukiko Morita:DO NOT have relevant financial relationships
| Toshihiro Nakamura:DO NOT have relevant financial relationships
| Kazuteru Fujimoto:No Answer
| Hiromi Matsubara:DO have relevant financial relationships
;
Advisor:MSD:Active (exists now)
; Speaker:AOP Health:Past (completed)
; Speaker:Nipro:Past (completed)
; Speaker:Bayer:Past (completed)
; Speaker:Nippon Shinyaku:Active (exists now)
; Speaker:Kaneka Medix:Active (exists now)
; Speaker:Mochida Pharmaceutical Co:Active (exists now)
; Speaker:Janssen:Active (exists now)
; Speaker:MSD:Active (exists now)
; Advisor:Bayer:Past (completed)
; Advisor:Janssen:Active (exists now)
| Toru Kato:No Answer
| Takashi Unoki:DO NOT have relevant financial relationships
| Daisuke Takagi:DO NOT have relevant financial relationships
| Kyohma Wada:DO NOT have relevant financial relationships
| Miyaka Wada:DO NOT have relevant financial relationships
| Masahiro Suzuki:DO NOT have relevant financial relationships
| Takumi Nakayama:DO NOT have relevant financial relationships
| Yuka Maeda:DO NOT have relevant financial relationships
| Nobutoyo Masunaga:DO NOT have relevant financial relationships
| Mitsuru Ishii:DO NOT have relevant financial relationships
| Kazuhiko Kotani:DO NOT have relevant financial relationships
| Mitsuru Abe:DO NOT have relevant financial relationships
| Masaharu Akao:DO have relevant financial relationships
;
Speaker:Pfizer:Active (exists now)
; Speaker:Daiichi Sankyo:Active (exists now)
; Speaker:Bayer Yakuhin:Active (exists now)
; Speaker:Bristol-Myers Squibb:Active (exists now)
| Koji Hasegawa:DO NOT have relevant financial relationships
| Hiromichi Wada:DO have relevant financial relationships
;
Research Funding (PI or named investigator):Abbott Japan LLC:Past (completed)
; Research Funding (PI or named investigator):Otsuka Pharmaceutical Co.,Ltd.:Past (completed)
; Research Funding (PI or named investigator):Teijin Pharma, Ltd:Past (completed)
; Research Funding (PI or named investigator):Kyowa Kirin Co., Ltd.:Past (completed)
; Research Funding (PI or named investigator):Daiichi Sankyo Co., Ltd.:Past (completed)
; Research Funding (PI or named investigator):Roche Diagnostics K.K.:Past (completed)
| Morihiro Matsuda:DO NOT have relevant financial relationships
| Yoichi Ajiro:DO NOT have relevant financial relationships
| Tsuyoshi Shinozaki:DO NOT have relevant financial relationships
| Satoru Sakagami:DO NOT have relevant financial relationships
| Kazuya Yonezawa:No Answer
| masatoshi shimizu:DO NOT have relevant financial relationships
| Junichi Funada:DO NOT have relevant financial relationships